{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:00:49Z","timestamp":1788843649190,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2007908"],"award-info":[{"award-number":["APP2007908"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["MRFF2007441"],"award-info":[{"award-number":["MRFF2007441"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009843","name":"South Australian Health and Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001786","name":"University of Adelaide","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000947","name":"Australian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011025","name":"Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health and Aged Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100109","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:58:04Z","timestamp":1745557084000},"page":"100109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-4081","authenticated-orcid":false,"given":"Elias","family":"Lagonik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-2574","authenticated-orcid":false,"given":"Elyse C.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-1824","authenticated-orcid":false,"given":"John B.","family":"Bruning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-7602","authenticated-orcid":false,"given":"Laura N.","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-6477","authenticated-orcid":false,"given":"Susan L.","family":"Heatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-2613","authenticated-orcid":false,"given":"Matthew","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-103X","authenticated-orcid":false,"given":"Chun Y.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-1779","authenticated-orcid":false,"given":"Andrew S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-333X","authenticated-orcid":false,"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bneo.2025.100109_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bneo.2025.100109_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V122.21.839.839","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100109_bib3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bneo.2025.100109_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2025.100109_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2025.100109_bib6","article-title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"14","author":"Saleh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bneo.2025.100109_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.bneo.2025.100109_bib8","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2025.100109_bib9","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study","volume":"8","author":"den Boer","year":"2021","journal-title":"Lancet Haematol"},{"issue":"139","key":"10.1016\/j.bneo.2025.100109_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.bneo.2025.100109_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","volume":"191","author":"Moorman","year":"2020","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.bneo.2025.100109_bib12","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"issue":"5531","key":"10.1016\/j.bneo.2025.100109_bib13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.bneo.2025.100109_bib14","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2025.100109_bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2014.256","article-title":"Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment","volume":"29","author":"Yeung","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100109_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv"},{"issue":"7647","key":"10.1016\/j.bneo.2025.100109_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.bneo.2025.100109_bib18","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bneo.2025.100109_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bneo.2025.100109_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bneo.2025.100109_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/10428194.2020.1861275","article-title":"In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy","volume":"62","author":"Heatley","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.bneo.2025.100109_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024776","article-title":"Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy","volume":"144","author":"Eadie","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100109_bib23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41375-024-02314-7","article-title":"The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib","volume":"38","author":"Leske","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2025.100109_bib24","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-024-02353-0","article-title":"Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib","volume":"38","author":"Leyte-Vidal","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2025.100109_bib25","article-title":"CML-593 the novel BCR::ABL1 allosteric inhibitor HS-10382\/TERN-701 is potent against mutations resistant to active site tyrosine kinase inhibitors (TKIs) and acts synergistically with TKIs in BCR::ABL1+ cancer cell lines","volume":"23","author":"Parsons","year":"2023","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100109_bib26","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1182\/blood-2022-168568","volume":"140","author":"Greenwood","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100109_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2353\/jmoldx.2009.080048","article-title":"Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia","volume":"11","author":"Morley","year":"2009","journal-title":"J Mol Diagn"},{"issue":"25","key":"10.1016\/j.bneo.2025.100109_bib28","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.bneo.2025.100109_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/(SICI)1097-0134(1997)1+<29::AID-PROT5>3.0.CO;2-J","article-title":"Homology modeling with internal coordinate mechanics: deformation zone mapping and improvements of models via conformational search","volume":"29","author":"Abagyan","year":"1997","journal-title":"Proteins"},{"issue":"3","key":"10.1016\/j.bneo.2025.100109_bib30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1006\/jmbi.1994.1052","article-title":"Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins","volume":"235","author":"Abagyan","year":"1994","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100109_bib31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/prot.340230314","article-title":"Homology modeling by the ICM method","volume":"23","author":"Cardozo","year":"1995","journal-title":"Proteins"},{"issue":"pt 10","key":"10.1016\/j.bneo.2025.100109_bib32","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation","volume":"65","author":"Moriarty","year":"2009","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"6","key":"10.1016\/j.bneo.2025.100109_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10822-012-9547-0","article-title":"Docking and scoring with ICM: the benchmarking results and strategies for improvement","volume":"26","author":"Neves","year":"2012","journal-title":"J Comput Aided Mol Des"},{"issue":"3","key":"10.1016\/j.bneo.2025.100109_bib34","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1097\/HS9.0000000000000193","article-title":"Efficacy of tyrosine kinase inhibitor therapy in a chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia With ZC3HAV1-ABL2 Fusion","volume":"3","author":"Decool","year":"2019","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.bneo.2025.100109_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.bneo.2025.100109_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967536.34543.a6","article-title":"Frontline asciminib combination in chronic phase chronic myeloid leukemia patients. The Fascination trial [abstract]","volume":"7","author":"Ernst","year":"2023","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.bneo.2025.100109_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100109_bib38","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/jm101506n","article-title":"Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class","volume":"54","author":"Salah","year":"2011","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bneo.2025.100109_bib39","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1074\/jbc.RA118.004732","article-title":"Structural insights into the tyrosine phosphorylation-mediated inhibition of SH3 domain-ligand interactions","volume":"294","author":"Mer\u0151","year":"2019","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bneo.2025.100109_bib40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s42003-022-03416-7","article-title":"Differences in ligand-induced protein dynamics extracted from an unsupervised deep learning approach correlate with protein\u2013ligand binding affinities","volume":"5","author":"Yasuda","year":"2022","journal-title":"Commun Biol"},{"issue":"45","key":"10.1016\/j.bneo.2025.100109_bib41","doi-asserted-by":"crossref","first-page":"35631","DOI":"10.1074\/jbc.M005401200","article-title":"c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines","volume":"275","author":"Brasher","year":"2000","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bneo.2025.100109_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1097-2765(03)00274-0","article-title":"Autoinhibition of Bcr-Abl through its SH3 domain","volume":"12","author":"Smith","year":"2003","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.bneo.2025.100109_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003863","article-title":"The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion","volume":"10","author":"D\u00f6lker","year":"2014","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100109_bib44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cell.2011.08.046","article-title":"Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis","volume":"147","author":"Grebien","year":"2011","journal-title":"Cell"},{"issue":"34","key":"10.1016\/j.bneo.2025.100109_bib45","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304611120","article-title":"A biophysical framework for double-drugging kinases","volume":"120","author":"Kim","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bneo.2025.100109_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1110\/ps.051782206","article-title":"An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen\/deuterium exchange and mass spectrometry","volume":"15","author":"Hochrein","year":"2006","journal-title":"Protein Sci"},{"issue":"17","key":"10.1016\/j.bneo.2025.100109_bib47","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100109_bib48","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood-2023-184647","article-title":"Asciminib is effective against ABL1 gene fusions in acute lymphoblastic leukemia but only when the ABL1 SH3 domain is present","volume":"142","author":"Eadie","year":"2023","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:59:50Z","timestamp":1762657190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000445"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100109","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100109"}}